(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.79%.
Rallybio's earnings in 2026 is $26,810,000.On average, 4 Wall Street analysts forecast RLYB's earnings for 2026 to be -$25,283,507, with the lowest RLYB earnings forecast at -$29,166,940, and the highest RLYB earnings forecast at -$20,803,533. On average, 3 Wall Street analysts forecast RLYB's earnings for 2027 to be -$19,769,817, with the lowest RLYB earnings forecast at -$18,994,530, and the highest RLYB earnings forecast at -$20,351,282.
In 2028, RLYB is forecast to generate -$17,133,841 in earnings, with the lowest earnings forecast at -$16,461,926 and the highest earnings forecast at -$17,637,778.